Published Results of EFUZEN Study Show Improved Sexual Function After UFE

 

April 6, 2017—The EFUZEN study was evaluated for changes in sexual function related to uterine fibroid embolization (UFE). The study, which found that UFE significantly improves all aspects of sexual function and quality of life at 1 year postembolization, were published online ahead of print in CardioVascular and Interventional Radiology by Hélène Vernhet-Kovacsik, MD, et al for the French Society of Interventional and Cardiovascular Imaging research group. The findings were presented in April 2016 at the Society of Interventional Radiology’s 2016 Annual Scientific Meeting in Vancouver, British Columbia.

The main goal of the study was to evaluate sexual function before and 1 year after UFE. The secondary goals were to evaluate the quality of life before and 1 year after UFE, as well as to determine the relationship between imaging findings (MRI data) before and 3 to 6 months after UFE and changes in sexual function and quality of life.

As summarized in CardioVascular and Interventional Radiology, this prospective, multicenter (25 centers) observational study enrolled a total of 264 consecutive symptomatic women undergoing UFE using Embozene (Boston Scientific Corporation) from March 2012 to May 2013.

The investigators calculated the Female Sexual Function Index [FSFI] score and the Uterine Fibroid Symptom Quality-of-Life (UFS-QOL) score before and 1 year after UFE. MRI was performed before and 3 to 6 months after UFE. The investigators recorded uterine and main fibroid volume and percentage of fibroid enhancement after injection of gadolinium. They also reviewed the impact of imaging data before and after FSFI scores and UFS-QOL scores after UFE.

Complete FSFI and USF-QOL scores were obtained in 170 and 192 women, respectively. At 1 year postprocedure, improvement of FSFI score was seen in 134 of 170 women (78.8%), USF-QOL scores were improved in 183 of 203 (90.2%), and symptom severity in 163 of 192 (84.9%). The relationship between main fibroid reduction, the decrease of fibroid enhancement, and global UFS-QOL and FSFI scores was not established, reported the investigators in CardioVascular and Interventional Radiology.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.